C
Christopher D. Turner
Researcher at ARIAD Pharmaceuticals, Inc.
Publications - 49
Citations - 2836
Christopher D. Turner is an academic researcher from ARIAD Pharmaceuticals, Inc.. The author has contributed to research in topics: Ponatinib & Population. The author has an hindex of 17, co-authored 49 publications receiving 2507 citations. Previous affiliations of Christopher D. Turner include University of Texas Southwestern Medical Center & Duke University.
Papers
More filters
Journal ArticleDOI
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes,Dong-Kee Kim,Javier Pinilla-Ibarz,P. le Coutre,Ronald Paquette,Charles Chuah,F. E. Nicolini,Jane F. Apperley,Hanna Jean Khoury,Moshe Talpaz,John F. DiPersio,Daniel J. DeAngelo,Elisabetta Abruzzese,Delphine Rea,Michele Baccarani,Martin C. Müller,Carlo Gambacorti-Passerini,Stephane Wong,Stephanie Lustgarten,Victor M. Rivera,Timothy P. Clackson,Christopher D. Turner,Frank G. Haluska,François Guilhot,Michael W. Deininger,Andreas Hochhaus,Timothy P. Hughes,J. M. Goldman,Neil P. Shah,Hagop M. Kantarjian +29 more
TL;DR: Ponatinib had significant antileukemic activity across categories of disease stage and mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91%.
Journal ArticleDOI
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes,Hagop M. Kantarjian,Neil P. Shah,Dale L. Bixby,Michael J. Mauro,Ian W. Flinn,Thomas O'Hare,Thomas O'Hare,Simin Hu,Narayana I. Narasimhan,Victor M. Rivera,Tim Clackson,Christopher D. Turner,Frank G. Haluska,Brian J. Druker,Michael W. Deininger,Michael W. Deininger,Moshe Talpaz +17 more
TL;DR: Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations.
Journal ArticleDOI
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor
Susan N. Chi,Mary Ann Zimmerman,Xiaopan Yao,Kenneth J. Cohen,Peter C. Burger,Jaclyn A. Biegel,Lucy B. Rorke-Adams,Michael J. Fisher,Anna J. Janss,Claire Mazewski,Stewart Goldman,Peter E. Manley,Daniel C. Bowers,Anne Bendel,Joshua B. Rubin,Christopher D. Turner,Karen J. Marcus,Liliana Goumnerova,Nicole J. Ullrich,Mark W. Kieran +19 more
TL;DR: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis CNS ATRT.
Journal ArticleDOI
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Christopher D. Turner,Sridharan Gururangan,James D. Eastwood,Krystal S. Bottom,Melody A. Watral,Rodney Beason,Roger E. McLendon,Allan H. Friedman,Sandra Tourt-Uhlig,Langdon L. Miller,Henry S. Friedman +10 more
TL;DR: CPT-11, given in this schedule, appears to be active in children with malignant glioma, medulloblastoma, and ependymoma with acceptable toxicity.
Journal ArticleDOI
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
David A. Reardon,James M. Schuster,David Tran,Karen Fink,Louis B. Nabors,Gordon Li,Daniela A. Bota,Rimas V. Lukas,Annick Desjardins,Lynn S. Ashby,J. Paul Duic,Maciej M. Mrugala,Andrea Werner,Thomas Hawthorne,Yi He,Jennifer Green,Michael Yellin,Christopher D. Turner,Thomas A. Davis,John H. Sampson +19 more
TL;DR: The investigational vaccine rindopepimut consists of an EGFRvIII constitutively active EGFR deletion driver mutation and a booster adjuvant that acts as a ‘spatially aggregating force’ to reprogram the EGFR into an ‘exciting’ substance.